Advanced molecular profiling test requires 40% fewer tissue slides than industry norm, allowing researchers and oncologists to test more patients with less precious tissue Guardant Health, Inc.

GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart ...

MADISON, Wis., Oct. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, ...

Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results Upgraded test ...

It is often said that the most disruptive and world-shaping ideas don’t come from a bolt of insight but are, instead, the response to a rejection. The emerging field of tissue engineering followed ...

A head-to-head study pitting Guardant Health’s lung cancer blood test against standard, tissue-based testing found that the liquid biopsy was able to deliver similar results much faster and with more ...

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Foundation Medicine, Inc., Flatiron Health, and Genentech, members of the Roche Group, in partnership with a network of community oncology practices, ...

PALO ALTO, Calif., November 10, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its Guardant Reveal® blood test to ...

PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ:GH), a precision oncology company whose stock has surged 178% over the past year and currently trades near its 52-week high, has introduced a new ...

The human kidney—a fist-sized organ that filters the body's blood supply—consists of more than 26 different cell types arranged to form complex structures. It bears little resemblance to the ...